Corxel US and Amanat Acquisition Corp Announce Definitive Business Combination Agreement to Create Publicly Listed Obesity-Focused Biopharmaceutical Company

Corxel US and Amanat Acquisition Corp announced a definitive merger agreement creating a publicly listed biopharmaceutical company focused on obesity treatment. This represents a capital-raising catalyst and clinical-stage company graduation to public markets, signaling investor conviction in the obesity therapeutic space that has experienced heightened institutional interest following blockbuster GLP-1 approvals.

The combined entity will advance CX11, a once-daily oral GLP-1 receptor agonist in Phase 2, which has demonstrated clinically meaningful weight loss with favorable tolerability. Critically, Corxel has achieved FDA alignment on Phase 3 trial design and regulatory pathway following an End-of-Phase 2 meeting—a major de-risking milestone reducing execution uncertainty and accelerating time-to-IND/approval potential relative to early-stage peers.

The $300 million PIPE commitment from tier-one investors including RTW Investments and NEA validates market enthusiasm for oral small-molecule obesity therapeutics as a differentiated alternative to inject-able GLP-1 franchises. This funding level suggests commercial confidence in CX11's clinical profile and market opportunity, de-risking near-term cash burn and funding Phase 3 through potential regulatory decision points.

Sector implication: The obesity-pharma subsector continues attracting capital and clinical talent, bolstering competition against established players. Public markets are pricing in sustained demand for obesity treatments across formulation types, supporting premium valuations for clinically advanced candidates with differentiated mechanisms and regulatory clarity.